《2026罕见病行业趋势观察报告》发布 解读罕见病行业发展新风向

Core Insights - The report highlights a significant systemic transformation in China's rare disease management in 2025, with breakthroughs across various key areas [2] Group 1: Policy Developments - The report provides a comprehensive overview of the latest policies related to rare diseases in China, marking the transition from a "policy building period" to a "system deepening period" [1] - Six new lists were released, including a panoramic view of rare disease-related policies, a list of approved rare disease treatment drugs, and a list of high-cost rare disease drugs not covered by insurance [1] Group 2: Industry Progress - Major advancements were noted in the construction of diagnostic and treatment systems, with systematic progress achieved [2] - A milestone breakthrough in the AI field for rare diseases was reported, indicating significant technological advancements [2] - The establishment of a multi-tiered payment structure was initiated with the introduction of a "dual directory" system [2] - Significant progress was made in the regulatory framework for special medical foods [2] - Local innovation in drug research and evaluation is accelerating, showcasing the rise of domestic capabilities [2] - Continuous support from social forces and technology platforms is evident, indicating a collaborative approach to rare disease management [2]